FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Lorazepam Injection
Status: Currently in Shortage
»Date first posted: 05/03/2018
»Therapeutic Categories: Neurology

Expand all

Akorn Pharmaceuticals (Reverified 05/19/2021)

Company Contact Information:
800-932-5676

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Lorazepam Injection 2 mg/mL (NDC 17478-040-01) Available Demand increase for the drug

Amphastar Pharmaceuticals, Inc./IMS (Reverified 05/06/2022)

Company Contact Information:
800-423-4136

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1) Available Other

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Reverified 04/08/2022)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10) This presentation is temporarily on backorder. Additional lots will be scheduled for manufacturing in the January 2022 timeframe. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug
Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10) Inventory is currently available. Additional lots are scheduled to be manufactured. Product will be made available as it is released. Demand increase for the drug

Hospira, Inc. (Revised 05/10/2022)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
4 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1539-31) Discontinued Discontinuation of the manufacture of the drug
2 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1985-30) Available Other
2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02) Next Delivery: May 2022; Estimated Recovery: October 2022 Demand increase for the drug
4 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6779-02) Discontinued Discontinuation of the manufacture of the drug
20 mg/10 mL (2 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-6780-02) Discontinued Discontinuation of the manufacture of the drug

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English